On July 19, the Medsintez plant arranged the first open excursion for schoolchildren as part of an educational Science program. It involved talented students from 30 municipalities of the Sverdlovsk Region. They have already learned most of the lecture material from such areas as the medicine of the future, chemistry and pharmacy. This July educational program was organized by the Golden Section Fund, which supports talented children and youth. The excursion to the plant promoted knowledge consolidation.
The educational project was launched in August 2017 as part of the Sverdlovsk region's state program named "Implementation of youth policy and patriotic education of citizens in the Sverdlovsk region until 2024" and has already proven its relevance.
During an excursion to the Medsintez plant, the participants of the educational shift were shown a lab and pharmaceutical production lines. They were told about possibilities of modern pharmacology and its prospects.
The Medsintez plant currently focuses on the production of infusion solutions and finished forms of genetically engineered human insulin. It is one of the first industrial manufacturers in Russia that produces finished dosage forms of genetically engineered human insulin, which meet GMP EC standards. The plant management sees further development prospects in manufacturing new types of medical products. The pharmaceutical direction is to be driven by implementation of some projects dealing with arranging the manufacturing of medicines and active pharmaceutical substances of genetic-engineered and analoginsulins (Aspart, Glargin) for subsequent use in our own production of finished dosage forms. The implementation of the project will allow to give up purchasing foreign substances and create a full-cycle insulin production.
The plant has also launched the production of Triazavirin, a domestic innovative drug, which is effective against more than 15 viral infections. The development was awarded the prestigious Prix Galien Russia prize. In 2017, the medication was included into the federal clinical guidelines of the Ministry of Health of the Russian Federation as one of four antiviral drugs for influenza. Triazavirin is currently undergoing additional clinical trials to expand its scope use. Doctors successfully use the drug not only with influenza, but also with acute respiratory viral infections, tick-borne encephalitis, hemorrhagic fevers and other conditions.
The active interaction of the plant’s management with the Talented Children and Youth Support Fund established by Sverdlovsk Region's Government, providing career-guidance support to educational projects, targeted support for children with outstanding abilities in natural sciences, scientific and technical creative activities are among the main components of the effective development and productive use of the innovative potential, whereof the main carriers are those who are still in school but are going to come to plants and research labs tomorrow.